Biomedical Journal (Oct 2022)

Targeting mitochondrial bioenergetics as a promising therapeutic strategy in metabolic and neurodegenerative diseases

  • Gurjit Kaur Bhatti,
  • Anshika Gupta,
  • Paras Pahwa,
  • Naina Khullar,
  • Satwinder Singh,
  • Umashanker Navik,
  • Shashank Kumar,
  • Sarabjit Singh Mastana,
  • Arubala P. Reddy,
  • P. Hemachandra Reddy,
  • Jasvinder Singh Bhatti

Journal volume & issue
Vol. 45, no. 5
pp. 733 – 748

Abstract

Read online

Mitochondria are the organelles that generate energy for the cells and act as biosynthetic and bioenergetic factories, vital for normal cell functioning and human health. Mitochondrial bioenergetics is considered an important measure to assess the pathogenesis of various diseases. Dysfunctional mitochondria affect or cause several conditions involving the most energy-intensive organs, including the brain, muscles, heart, and liver. This dysfunction may be attributed to an alteration in mitochondrial enzymes, increased oxidative stress, impairment of electron transport chain and oxidative phosphorylation, or mutations in mitochondrial DNA that leads to the pathophysiology of various pathological conditions, including neurological and metabolic disorders. The drugs or compounds targeting mitochondria are considered more effective and safer for treating these diseases. In this review, we make an effort to concise the available literature on mitochondrial bioenergetics in various conditions and the therapeutic potential of various drugs/compounds targeting mitochondrial bioenergetics in metabolic and neurodegenerative diseases.

Keywords